All In Biotech

Drug Trial Radar · NCT05308264

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

86

Planned (sponsor's estimate)

Start

Sep 12, 2022

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Rigel PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)

Conditions

  • Low Risk Myelodysplastic Syndromes

Interventions

  • R906289 Monosodium (R289 Na)Drug

    Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd, 250mg PO bid, 500 mg PO qd, 500 mg PO bid, 750 mg PO qd, split dose - 500 mg PO AM/250 mg PO PM)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: 2 Year

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • University of California, Irvine

    Orange, California · Recruiting

  • Stanford Cancer Institute

    Palo Alto, California · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • WashU Medicine

    St Louis, Missouri · Recruiting

  • Oncology Clinical Research Referral Office

    Hackensack, New Jersey · Recruiting

  • Ichan School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • University of Texas, Southwestern

    Dallas, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Intermountain Healthcare

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.